Placebo Your Bets: Prediction Markets Enter Biotech

Good morning, Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

Imagine you could "bet" on the outcome of a clinical trial.

Not through an investment.

But actually a binary “YES/NO” trial outcome.

Like placing a wager on a football match.

It’s coming.

… and it scares me.

Last week, Kalshi launched its first prediction markets for FDA approvals and Phase 3 clinical trials:

This is different to investing in stock.

The value of a stock is determined by its assets, market cap, cash balance, share price, and supply and demand.

This bet is JUST on the results of the trial.

One drug. One endpoint. One price.

Prediction markets have exploded in popularity in the US ever since the last US election, where Polymarket correctly predicted Donald Trump as the frontrunner for the US presidency - despite polls to the contrary.

But when prediction markets enter the regulated stock market space, issues arise.

Insider trading, governance, market manipulation.

Earlier this year, a Google employee was charged with using confidential "Year in Search" data to make around US$1.2 million trading Polymarket contracts.

AND Goldman Sachs has since banned its own staff from betting on markets tied to finance, companies and politics.

But these markets are gaining legitimacy… whether we like it or not.

Polymarket has partnered with Dow Jones to provide prediction market data to The Wall Street Journal, while Kalshi provides data to both CNN and CNBC.

Prediction markets are here, and consumers have voted with their attention and wallets.

But what about healthcare… our sector?

What happens when we mix prediction markets with healthcare outcomes… specifically clinical trials?

We have our own unique set of challenges (and opportunities) that go beyond market integrity.

Namely, patient integrity, trial integrity and ethics.  

So today, my deep dive is to answer the simple question..

What does the biotech landscape look like in the age of prediction markets?

But first…

Clinuvel Pharmaceuticals (ASX: CUV) will commence trading its ADS on NASDAQ’s Global Select Market under the ticker CUVL. (CUV)

🪑  It will be interesting to see if this brings some US attention to the stock/story. 

It certainly unlocks the US investor market, but penetrating it is the next challenge.

LTR Pharma Limited (ASX: LTP) executes a definitive commercial agreement with Strive Pharmacy for nationwide manufacturing and distribution of nasal spray erectile dysfunction product ROXUS in the U.S. (LTP)

🪑 A second deal confirming a binding termsheet. Looks like LTR Pharma are gearing up to commercialise its product soon.

Imricor Medical Systems (ASX: IMR) submits all remaining FDA 510(k) devices for FDA clearance. (IMR)

🪑 More than 50,000 pages of product and regulatory documentation is epic. 

Looks like they will have a product ready to sell in-market early next year.

Nice work.

PainChek Ltd (ASX: PCK) appoints US-based Karen Holzberger as CEO, following its expansion efforts in the US post-FDA De Novo clearance. (PCK)

🪑 Looks to be a sales-based and commercial scale-up CEO hire.

Microba Life Sciences (ASX: MAP) extends its agreement with SYNLAB to distribute its Microbiome Explorer platform across Europe and Latin America. (MAP)

Syntara Limited (ASX: SNT) completes the first cohort for its amsulostat product in combination with chemotherapy for leukemia. No toxicities. Data from the Phase 1 trial scheduled for Q4 2026. (SNT)

🪑 Milestone ticked.

Entropy Neurodynamics (ASX: ENP) announces a South African patent grant for psilocybin-based fibromyalgia treatments. (ENP)

Doctor Care Anywhere (ASX: DOC) receives ASX relief from quarterly reporting due to consistent cash generation and profitability. (DOC)

OncoSil Medical (ASX: OSL) receives approval from the Saudi FDA for its OncoSil™ device. (OSL)

Recce Pharmaceuticals (ASX: RCE) extends its SPP closing date, allowing shareholders to buy shares at A$0.40 each. (RCE)

🪑 Not a great sign if the SPP date is extended, trading below the SPP price.

Report: The Wall Street Journal published a great video documentary on the commercialisation of DMT for depression. (WSJ)

🪑 The psychedelic macro thematic is going mainstream.

ECS Botanics Holdings (ASX: ECS) reports a fourth consecutive positive operating cash flow quarter with $310k. Unaudited FY26 revenue increased by 8% to $21 million. (ECS)

🪑 Decent financial year for ECS - operational cash flow positive is what you want to see. 

Growth still in single digits, but heading in the right direction.

First, what is a prediction market?

A prediction market is a place where you buy and sell contracts that pay out based on whether a real-world event happens.

The price becomes a live probability.

So if a contract trades at 70 cents, the crowd is saying there's a 70% chance.

It all stems back to an old idea…

Give a market enough liquidity and enough eyeballs, and it should "price" the event efficiently, so the number lands close to the true, real-world probability.

The wisdom of the crowd.

Having an accurate outlook on the future probabilities is important.

In terms of both making decisions and managing risk.

The issue with traditional polls, analyst forecasts, and even traditional markets is that there is a lot of inherent bias and conflicts of interest that drive forecasts and predictions.

(And, in turn, decisions)

BUT, if you pool enough informed people AND make them back their views with their own money, you get a faster, sharper read on the future.

That’s the theory anyway.

Prediction markets are positioned as the purest form of collective intelligence.

In reality, I believe that they are just as manipulated and fraught as any market.

But potentially even worse, given that they are largely unregulated.

Last week, Kalshi announced a pilot partnership with AppliedXL to launch prediction markets on clinical trial outcomes and FDA regulatory decisions.

For the first time, individuals can buy a contract on whether a specific drug hits its Phase 3 endpoint or the FDA approves it by a certain date.

These are binary “YES/NO” contracts that close on a specific outcome… with the contract price moving in real time as a live probability.

Here is one of the live contracts for Compass Pathways Phase 3 for psychedelic medicine:

As you can see, the odds of the clinical trial outcome YES before July 2027 improved in early April after the Trump executive order… then again in late April when Compass Pathways was granted a priority review voucher.

To maintain clinical trial integrity, Kalshi has implemented two guardrails.

FIRST, late-stage only. 

Phase 3 trials at established companies (generally market caps over US$500 million), full approvals only, no early-phase exploratory endpoints, no conditional decisions.

SECOND, a contract only lists after a trial has finished enrolling.

This is so a visible price can't bend patient recruitment or physician referrals. 

Every contract resolves against a named public document, the ClinicalTrials.gov primary endpoint, the FDA approval letter, or the advisory committee vote, and Kalshi requires employment verification to screen out insiders.

How is this different to just investing in a stock?

If you own a biotech stock, you're taking on the risk and opportunity with the entire company.

Not just the trial…

The balance sheet, the come-raise, supply-chain risk, management, all factor into a stock’s “price”.

A contract lets you express a view on the science itself, on its own terms.

Here is the quote from the AppliedXL whitepaper:

If you want to know more about prediction markets in biotech, that whitepaper is worth a read.

Also, there is a great conversation on STAT’s The Readout LOUD podcast published this week with Jonathan Kimmelman, bioethicist at McGill University, who actually researches prediction in clinical trials:

So, it’s happening.

Individuals will be able to start betting on clinical trials… 

What are the downstream effects?

In 2003, Eli Lilly ran an experiment.

About fifty employees traded six of the company's drug candidates through an internal market

Chemists, biologists, project managers, etc.

It worked better than almost anyone expected, ranking the candidates more accurately than Lilly's own process and correctly picking the three that went on to be most successful.

What the trading revealed was the range.

Someone willing to pay $70 for a candidate was showing more conviction than a $60 bidder.

You don’t get that from a show of hands.

The theory is that prediction markets are efficient aggregators of information, and they outperform decisions made by a select few… 

No single person knows everything, but a market lets people who are each "touching different parts of the elephant" come together, and the price reflects their combined knowledge.

Under the right conditions, that can get you close to the truth.

Better predictions make for better capital allocation decisions. 

Less waste on failed clinical trials.

Less Immuteps. Less Optheas.

That’s the upside.

Picture a market pricing a drug at 85% to succeed.

If you're a patient and you find out you might be in the placebo arm of a trial for a drug the whole world already thinks works, what do you do? 

You get bummed out. You drop out. You over-report the side effects you were hoping to avoid. 

Physicians, consciously or not, start assessing patients differently. 

And blinding doesn't save you; plenty of pivotal trials aren't blinded, and even in blinded ones, patients often work out which arm they're in.

ALSO, if the prediction on a trial has an incredibly low chance of, let's say 10%... would you bother recruiting into the trial?

This is a big trial integrity challenge.

Kalshi has tried to resolve this by only publishing markets where recruitment is complete.

But the cat is out of the bag.

If consumer demand to “bet” on a live trial emerges, it will happen.

Clinical trials run on privileged, unblinded information. 

Lead investigators, biostatisticians, safety-monitoring committee members, sponsor employees. 

Major markets like the NASDAQ and the ASX employ market monitoring tactics to avoid insider trading and insider information.

In its inaugural ASX Supervision Report, the ASX specifically calls out the examination and handling of clinical trial data held by third parties as a high-potential risk for the industry.

(and a focus for the regulator in 2027) 

Kalshi's answer is employment verification and monitoring.

But this is a much lower bar when compared to the sophistication of market trading and monitoring employed by the ASX and other regulated markets.

Good luck policing that at scale. 

Around this year's Super Bowl, Kalshi disclosed that it had opened roughly 200 insider-trading investigations in sports and entertainment.

…that's for guessing who wins the game.

Now imagine the incentive when the "insider" is a biostatistician who has actually seen the unblinded survival curve.

There are real-world implications for this.

Stock price changes for publicly listed companies as well as health outcomes for patients.

If not properly monitored, then the integrity of the entire process could come into question.

… which is essentially the basis for running large, expensive phase 3 clinical trials and getting drugs to market.

What underpins a late-stage clinical trial is integrity.

Integrity of the data…

Integrity of the placebo…

Integrity of the statistical power…

Integrity of the double-blind standard…

… and the integrity of confidentiality.

IF prediction markets ruin that integrity, then it doesn't matter what predictive benefit we might get from the "wisdom of the crowd".

Because the thing we'd be trading on is the very thing we'd be breaking.

A market that corrupts the trial can't also be trusted to price it.

That’s my take…

But what do I know?

I’m just an Armchair Analyst.

See you tomorrow,

The Armchair Analyst.